Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials

Li, Cunfu; Xiang, Aizhai; Chen, Xianzhi; Yin, Kai; Lu, Jinsong; Yin, Weiqiang

doi:10.2147/ott.s138600

Cited by 5 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13.3%). Meta‐analyses of these phase III studies confirmed the lack of an OS benefit along with potentially severe adverse events in the bevacizumab arm 47,48 . The FDA withdrew the approval of bevacizumab for breast cancer, but NCCN Guidelines retain the recommendation of bevacizumab plus paclitaxel.…”

Section: Vegf Inhibitorsmentioning

confidence: 91%

“…Meta-analyses of these phase III studies confirmed the lack of an OS benefit along with potentially severe adverse events in the bevacizumab arm. 47 , 48 The FDA withdrew the approval of bevacizumab for breast cancer, but NCCN Guidelines retain the recommendation of bevacizumab plus paclitaxel. Bevacizumab actually has therapeutic effects in patients with HER2-negative breast cancer, however there is no concerted conclusion on the specific role of bevacizumab in adjuvant chemotherapy, the indications of which need further verification.…”

Section: Vegf Inhibitorsmentioning

confidence: 99%

See 1 more Smart Citation

Progress in targeted therapy for breast cancer

Zhu

Yuan

2018

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty of signaling pathways and correspondingly therapeutic targets in breast cancer, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), phosphoinositide-3-kinase (PI3K), v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted therapy, which optimizes the accuracy of antitumor activity and minimizes toxicity to normal tissues, plays a crucial role in breast cancer treatment in the era of precision medicine. In this review, we aimed to summarize the latest developments in targeted therapy for breast cancer and discuss the existing problems.

show abstract

Section: Vegf Inhibitorsmentioning

confidence: 91%

Section: Vegf Inhibitorsmentioning

confidence: 99%

Progress in targeted therapy for breast cancer

Zhu

Yuan

2018

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

show abstract

“…Manifold data have demonstrated that the addition of bevacizumab to chemotherapy improved progression-free survival (PFS), while few trials have revealed its significant overall survival (OS) benefit. Furthermore, it still remains suspended how to maximize the benefits of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer (38).…”

Section: Anti-vegf Agentsmentioning

confidence: 99%

Therapeutic Applications of Vegf Inhibitors in Breast Cancer.

Balawi¹

2018

IJAR

View full text Add to dashboard Cite

“…However, clinical trials have consistently shown that the addition of bevacizumab to taxanes, in particular paclitaxel, confers a significant benefit in terms of progression-free survival (PFS) compared with taxanes alone [9, 11–13]. The combination of bevacizumab plus paclitaxel is approved for use in the EU as a first-line treatment for women with HER2-negative metastatic breast cancer [14].…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Petitjean¹,

Smith-Palmer²,

Valentine³

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

BackgroundEvidence from clinical trials suggests that the addition of bevacizumab to chemotherapy in the first-line treatment of patients with HER2-negative metastatic breast cancer improves progression-free survival (PFS) but not overall survival (OS). However, a retrospective analysis of real-world data from the French Comprehensive Cancer Centers (FCCC) through the Epidemiological Strategy and Medical Economics (ESME) Research Program, suggested that in this setting, the addition of bevacizumab may confer a significant benefit in terms of both PFS and OS. A cost-effectiveness analysis was performed to determine the cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel alone in the first-line treatment of HER2-negative metastatic breast cancer at specialist oncology centers in France.MethodsThe analysis was performed using a three-state Markov model and clinical input data from N = 3426 HER2-negative metastatic breast cancer patients treated with bevacizumab plus paclitaxel or paclitaxel alone. The analysis was performed from a third party payer perspective over a 10-year time horizon; future costs and clinical outcomes were discounted at 4% per annum.ResultsIn the overall population, the addition of bevacizumab to paclitaxel led to incremental gain of 0.72 life years and 0.48 quality-adjusted life years (QALYs) relative to paclitaxel alone. The incremental lifetime cost of the addition of bevacizumab was EUR 27,390, resulting in an incremental cost-effectiveness ratio (ICER) of EUR 56,721 per QALY gained for bevacizumab plus paclitaxel versus paclitaxel alone. In a subgroup of triple negative patients the ICER was EUR 66,874 per QALY gained.ConclusionsThe analysis indicated that the combination of bevacizumab plus paclitaxel is likely to be cost-effective compared with paclitaxel alone for the first-line treatment of HER2-negative metastatic breast cancer in specialized oncology centers in France.

show abstract

Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials

Cited by 5 publications

References 28 publications

Progress in targeted therapy for breast cancer

Progress in targeted therapy for breast cancer

Therapeutic Applications of Vegf Inhibitors in Breast Cancer.

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Contact Info

Product

Resources

About